- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07711990
Effects of Acute Ketone Supplementation on the Brain (KETO-BRAIN)
Effects of Acute Ketone Supplementation on the Brain [KETO-BRAIN]
The purpose of this study is to determine how a ketone ester supplement affects brain function, brain blood flow, and brain metabolism in healthy middle-aged and older adults. Ketones are naturally produced by the body during periods of fasting or carbohydrate restriction and serve as an alternative fuel source for the brain. Researchers are interested in whether increasing blood ketone levels through supplementation can alter brain activity and blood flow in ways that may support healthy brain function.
Participants will consume a ketone ester supplement and a placebo in separate study visits. Brain imaging, blood measurements, and cognitive testing will be used to evaluate the effects of each intervention. Findings from this study will help researchers better understand how ketones influence the healthy aging brain and may provide preliminary data for future studies in populations at risk for cognitive decline.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Alzheimer's disease and other age-related neurodegenerative conditions are associated with changes in brain energy metabolism that can occur years before symptoms develop. One of the earliest findings in these conditions is reduced utilization of glucose by certain brain regions. Ketones, including beta-hydroxybutyrate, can serve as an alternative fuel source for the brain and may help support brain metabolism when glucose utilization is impaired. Experimental evidence also suggests ketones may influence cerebral blood flow, neurotransmitter balance, and functional brain connectivity.
Despite growing interest in ketone supplementation, the acute effects of ketone esters on multiple aspects of human brain function have not been comprehensively evaluated. This study will investigate whether acute ketone ester ingestion alters cerebral blood flow, brain neurochemistry, resting-state brain connectivity, and cognitive performance in healthy adults.
This is a randomized, double-blind, placebo-controlled crossover study. Participants will complete two intervention periods, receiving a ketone ester supplement during one period and a calorie-matched placebo during the other. The order of interventions will be randomized and separated by a washout period of 3 to 7 days. Participants will consume study beverages for two days prior to each testing session and will undergo detailed testing following an overnight fast.
At each testing visit, participants will provide fingerstick blood samples to measure ketone and glucose concentrations, complete standardized cognitive testing, and undergo advanced magnetic resonance imaging (MRI). Brain imaging will include arterial spin labeling (ASL) to evaluate cerebral blood flow, proton magnetic resonance spectroscopy (1H-MRS) to assess brain metabolite and neurotransmitter concentrations, and functional MRI (fMRI) to assess resting-state brain network connectivity. Cardiac MRI measures will also be collected to explore relationships between cardiovascular and cerebrovascular responses.
The primary goal is to determine whether acute ketone supplementation changes cerebral blood flow, brain metabolite concentrations, and functional brain connectivity compared with placebo. Secondary analyses will evaluate relationships between blood ketone concentrations, imaging measures, and cognitive performance. Results from this pilot study will provide important mechanistic information regarding how ketones affect the healthy aging brain and will support the development of future clinical trials in populations at risk for cognitive impairment.
The study lasts about two weeks. There are two main test days with 3-7 days in between. Each testing session will last up to 3.5 hours at most.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Christopher Crabtree, Ph.D.
- Número de teléfono: 614-688-5623
- Correo electrónico: Christopher.Crabtree@osumc.edu
Ubicaciones de estudio
-
-
Ohio
-
Columbus, Ohio, Estados Unidos, 43210
- Reclutamiento
- The Ohio State University
-
Contacto:
- Christopher Crabtree, Ph.D.
- Número de teléfono: 614-688-5623
- Correo electrónico: Chrisstopher.Crabtree@osumc.edu
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Age ≥45 years and ≤65 years
- Able to comply with study requirements including presenting for each test session following an overnight fast and not following a ketogenic diet during the duration of the study.
- BMI between 18.5 and 30 kg/m2
Exclusion Criteria:
- Non-English Speaking
- Currently taking a ketone ester supplement, ketone salt supplement, or on a ketogenic diet
- Pregnancy, a urine pregnancy test will be given to all women before scanning to confirm nonpregnant status
- Currently breastfeeding
- Allergies to components in the test products, including milk protein, and not lactose intolerant
- History of high blood pressure
- History of alcoholism (previous 2 years)
- History of illicit drug use
- History of head trauma involving loss of consciousness or skull fracture
- Diagnosed neurological disease
- Taking psychiatric prescriptive medications (antipsychotics, antidepressants, or barbiturates) or over-the-counter (OTC) medications (other than those taken as nutritional supplements for non-therapeutic indications)
- Current smoker
- Currently consuming a habitual ketogenic diet, or was consuming a habitual ketogenic diet in the past three months
- Any condition or material in the body that is a contraindication for MRI procedures
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Ciencia básica
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación cruzada
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: Ketone Supplement drink
Drink contains 25 g of C8 Diester , 50g consumed total per day using split dose
|
The ketone ester beverage contains 25 g of C8 Diester emulsified in a matrix of water, whey protein concentrate, modified gum acacia, natural and artificial flavors and cocoa powder. It contains 210 kcal, 0.5 g fat, 2 g carbohydrates, and 2 g protein. Dose consumed is 50 g, 2 times per day for 2 days. The placebo (PL) will be calorie and volume matched to the KE and be formulated with standard dietary ingredients. |
|
Comparador de placebos: Placebo Drink
Drink contains no ketones, kcal and volume matched
|
The placebo drink will be calorie and volume matched to the KE and be formulated with standard dietary ingredients.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Cerebral Blood Flow
Periodo de tiempo: Acute response following 2-day lead in
|
To detect a clinically meaningful difference in cerebral blood flow (CBF) between ketone ester and placebo conditions in healthy adults
|
Acute response following 2-day lead in
|
|
Brain Glutamate Concentration
Periodo de tiempo: Acute response following 2-day lead in
|
To detect a difference in brain glutamate concentration (mM) between ketone ester and placebo conditions in healthy adults, measured using proton magnetic resonance spectroscopy (1H-MRS).
|
Acute response following 2-day lead in
|
|
Brain GABA Concentration
Periodo de tiempo: Acute response following 2-day lead in
|
To detect a difference in brain gamma-aminobutyric acid (GABA) concentration (mM) between ketone ester and placebo conditions in healthy adults, measured using proton magnetic resonance spectroscopy (1H-MRS).
|
Acute response following 2-day lead in
|
|
Brain Lactate Concentration
Periodo de tiempo: Acute response following 2-day lead in
|
To detect a difference in brain lactate concentration (mM) between ketone ester and placebo conditions in healthy adults, measured using proton magnetic resonance spectroscopy (1H-MRS).
|
Acute response following 2-day lead in
|
|
Brain Choline Concentration
Periodo de tiempo: Acute response following 2-day lead in
|
To detect a difference in brain choline concentration (mM) between ketone ester and placebo conditions in healthy adults, measured using proton magnetic resonance spectroscopy (1H-MRS).
|
Acute response following 2-day lead in
|
|
Brain N-Acetylaspartate (NAA) Concentration
Periodo de tiempo: Acute response following 2-day lead in
|
To detect a difference in brain N-acetylaspartate (NAA) concentration (mM) between ketone ester and placebo conditions in healthy adults, measured using proton magnetic resonance spectroscopy (1H-MRS).
|
Acute response following 2-day lead in
|
|
Brain Glucose Concentration
Periodo de tiempo: Acute response following 2-day lead in
|
To detect a difference in brain glucose concentration (mM) between ketone ester and placebo conditions in healthy adults, measured using proton magnetic resonance spectroscopy (1H-MRS).
|
Acute response following 2-day lead in
|
|
Brain Beta-Hydroxybutyrate (BHB) Concentration
Periodo de tiempo: Acute response following 2-day lead in
|
To detect a difference in brain beta-hydroxybutyrate (BHB) concentration (mM) between ketone ester and placebo conditions in healthy adults, measured using proton magnetic resonance spectroscopy (1H-MRS).
|
Acute response following 2-day lead in
|
|
Functional Brain Connectivity
Periodo de tiempo: Acute response following 2-day lead in
|
Change in resting-state brain network connectivity measured using blood oxygen level-dependent functional magnetic resonance imaging (BOLD-fMRI).
|
Acute response following 2-day lead in
|
|
Brain Acetoacetate Concentration
Periodo de tiempo: Acute response following 2-day lead in
|
To detect a difference in brain acetoacetate concentration (mM) between ketone ester and placebo conditions in healthy adults, measured using proton magnetic resonance spectroscopy (1H-MRS).
|
Acute response following 2-day lead in
|
|
Brain Glutamine Concentration
Periodo de tiempo: Acute response following 2-day lead in
|
To detect a difference in brain glutamine concentration (mM) between ketone ester and placebo conditions in healthy adults, measured using proton magnetic resonance spectroscopy (1H-MRS).
|
Acute response following 2-day lead in
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Blood Ketone Concentration
Periodo de tiempo: Acute response following 2-day lead in
|
Blood beta-hydroxybutyrate concentrations measured by fingerstick testing.
|
Acute response following 2-day lead in
|
|
Blood Glucose Concentration
Periodo de tiempo: Acute response following 2-day lead in
|
Blood glucose concentrations measured by fingerstick testing.
|
Acute response following 2-day lead in
|
|
Cognitive Performance (RBANS Total Scale Score)
Periodo de tiempo: Acute response following 2-day lead in
|
Total Scale Score on the RBANS, comparing ketone ester and placebo conditions in healthy adults.
|
Acute response following 2-day lead in
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
- STUDY20251460
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Salud cerebral
-
University of Dublin, Trinity CollegeDesconocidoAtletas de élite retirados de Brain Health
-
Queens College, The City University of New YorkReclutamientoPublicación de artículos enviados al American Journal of Public HealthEstados Unidos
-
WestatPlasma Protein Therapeutics AssociationAún no reclutandoHealth Effects (Niveles de Ferritina, Niveles de PCR, Niveles de IgG, Salud Auto-reportada)Estados Unidos
-
Assiut UniversityTerminadoMorfometría basada en Brain Voxel en ManiaEgipto
Ensayos clínicos sobre Ketone Ester Drink
-
Fresenius KabiTerminadoNutrición enteralAlemania
-
TCI Co., Ltd.ReclutamientoTrastorno de ansiedad depresión | Trastorno del sueño (trastorno)Taiwán
-
TCI Co., Ltd.Terminado
-
Fresenius Kabi Taiwan Ltd.TerminadoCáncer | Desnutrición (Calorías)Taiwán
-
University of FloridaTerminadoEnfermedad de Parkinson | CetosisEstados Unidos
-
Insel Gruppe AG, University Hospital BernRetirado
-
St Patrick's Hospital, IrelandDesconocidoTrastorno por consumo de alcoholIrlanda
-
University of Sao PauloTerminadoTrastornos TemporomandibularesBrasil
-
Washington University School of MedicineChildren's Discovery InstituteReclutamientoObesidad | Sobrepeso (IMC > 25) | MASLD: enfermedad hepática esteatósica asociada a disfunción metabólicaEstados Unidos
-
Instituto Nacional de Ciencias Medicas y Nutricion...Activo, no reclutandoDieta, Saludable | Hábito de la dieta | Nutrición, Saludable | Exposición dietéticaMéxico